We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

TCMD:NASDAQTactile Systems Technology, Inc. Analysis

Data as of 2026-05-04 - not real-time

$22.22

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Tactile Systems Technology (TCMD) is trading at $22.22, well below its DCF-derived fair value of $50.73 and the mean analyst target of $38, suggesting a sizable upside. The stock’s PE ratio of 27.1 exceeds the industry average of 25.5, but the forward PE of 15.1 reflects improving earnings expectations. Margins remain robust with a gross margin of 76% and an operating margin of 18%, while cash on hand ($83.4M) comfortably exceeds debt ($15.96M). Technical metrics show the price is near the identified support level of $22.12, the 20‑day SMA (24.22) is above the 50‑day SMA (26.26) indicating a neutral but slightly bearish alignment, and the RSI of 32 points to a modest oversold condition. Volume is on an increasing trend, providing liquidity support for potential upside moves. Recent news highlights a consistent fair‑value estimate of $38 and strong Q4 earnings that beat expectations, reinforcing confidence in the upside narrative.
The combination of strong cash generation, low debt, and a 71% upside potential from the DCF model positions TCMD as an attractive entry point for investors seeking growth in the medical‑device niche. While the sector carries medium regulatory risk, the company’s focused product portfolio and US‑centric exposure limit geographic and currency concerns. Given the current valuation gap and supportive fundamentals, a buy stance is warranted across short, medium, and long horizons, with increasing conviction as the price approaches key technical levels.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Price near support at $22.12
  • RSI indicating oversold conditions
  • Valuation upside of >70% versus fair value

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Strong revenue growth (21% YoY) and high margins
  • Forward PE of 15 suggesting earnings acceleration
  • Analyst mean target of $38 reinforcing upside

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Robust cash position and low debt
  • Sustainable product demand in chronic disease management
  • DCF fair value indicating 71% upside potential

Key Metrics & Analysis

Financial Health

Revenue Growth21.00%
Profit Margin5.79%
P/E Ratio27.1
ROE8.77%
ROA6.40%
Debt/Equity7.29
P/B Ratio2.3
Op. Cash Flow$42.8M
Free Cash Flow$34.6M
Industry P/E25.5

Technical Analysis

TrendNeutral
RSI32.2
Support$22.12
Resistance$26.86
MA 20$24.22
MA 50$26.26
MA 200$21.85
MACDBearish
VolumeIncreasing
Fear & Greed Index88.52

Valuation

Fair Value$50.73
Target Price$38.00
Upside/Downside71.02%
GradeUndervalued
TypeGrowth

Risk Assessment

Beta1.00
Volatility35.88%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.